No Data
Fate Therapeutics Price Target Cut to $5.00/Share From $7.00 by Wedbush
Fate Therapeutics Price Target Cut to $5.00/Share From $7.00 by Wedbush
Fate Therapeutics Is Maintained at Neutral by Piper Sandler
Fate Therapeutics Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Neutral on Fate Therapeutics, Lowers Price Target to $4
Piper Sandler analyst Edward Tenthoff maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from $7 to $4.
Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating
Fate Therapeutics (FATE) has an average rating of outperform and price targets ranging from $5 to $12, according to analysts polled by Capital IQ. Price: 3.8614, Change: -0.04, Percent Change: -0.99